Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated
pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular
carcinoma (HCC) setting. No hypothesis testing will be performed.
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
FAST (Focused Abbreviated Screening Technique)-MRI Study
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated
Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for
screening of liver cancer. Blood markers will be evaluated to determine their correl...
Age: 18 years - 66+
Gender: All
Study of SRF388 in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Age: 18 years - 66+
Gender: All
Study of SRF388 in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and
pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in
participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary
...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and
pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in
participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary
...
Age: 18 years - 66+
Gender: All
A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully
human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human
antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will...
Age: 18 years - 66+
Gender: All
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (which t...
Age: 18 - 99 years
Gender: All
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
The primary objective of the study is to evaluate the clinical activity of neoadjuvant
cemiplimab therapy in patients with resectable Non-small cell lung cancer (NSCLC),
Hepatocellular carcinoma (HCC), and Head and neck squamous cell carcinoma (HNSCC) lesions, as
...
Age: 18 years - 66+
Gender: All
Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance
testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein
biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not...
Age: 18 years - 66+
Gender: All
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissu...
Age: 18 years - 66+
Gender: All
A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The Expansion part of the study will evaluate objective response rate and duration ...
Age: 18 years - 66+
Gender: All
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as
hepatocellular carcinoma or HCC, while it is still in the liver. Many treatments exist to
treat tumors in the liver when they are small but after they grow past a certain size, local...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Ge...
Age: 18 years - 66+
Gender: All